We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study.
- Authors
Ljung, T.; Ahlberg, A.-C.; Holm, G.; Friberg, P.; Andersson, B.; Eriksson, E.; Björntorp, P.; Björntorp, P
- Abstract
<bold>Objective: </bold>To investigate the effects of a selective serotonin reuptake inhibitor (SSRI) on the neuroendocrine and autonomic nervous system perturbations found in abdominal obesity.<bold>Design: </bold>Treatment for 6 months with citalopram and for 6 months with placebo using a double-blind, cross-over design, with a 2-month wash-out period between treatment periods.<bold>Subjects: </bold>Sixteen healthy men, 45-60 years, moderately obese and with an abdominal fat distribution.<bold>Measurements: </bold>Anthropometry, three different depression rating scales, serum lipids, testosterone, IGF-I, oral glucose tolerance test (OGTT), pituitary stimulation with corticotropin releasing hormone (CRH), arithmetic stress test, and excretion of cortisol and metoxycatecholamines in urine, collected during 24 h.<bold>Results: </bold>Cortisol concentrations in the morning were low before treatment, indicating a perturbed function of the hypothalamic-pituitary-adrenal (HPA) axis. After treatment with citalopram morning cortisol concentrations rose to normal. Cortisol concentrations after stimulation with CRH or stress were elevated by citalopram treatment, but urinary cortisol excretion was unchanged. The glucose concentrations after OGTT (120 min) tended to be reduced, with unchanged insulin concentrations, whilst other metabolic values did not change during treatment. Heart rate after administration of CRH, and during laboratory stress test, decreased by treatment with citalopram. Diurnal urinary excretion of metoxycatecholamines tended to decrease. Neither body mass index nor waist/hip circumference ratio decreased. Depression scores were within normal limits before treatment and did not change.<bold>Conclusion: </bold>The results of this pilot study indicate improvements in the regulation of neuroendocrine-autonomic systems as well as metabolism in abdominal obesity during treatment with an SSRI.
- Subjects
SEROTONIN; OBESITY treatment; HYPOTHALAMIC-pituitary-adrenal axis; HYDROCORTISONE; CATECHOLAMINES; CHEMICAL inhibitors; EXCRETION; CLINICAL trials; COMPARATIVE studies; CROSSOVER trials; ENDOCRINE glands; GLUCOSE tolerance tests; HYPOTHALAMUS; INSULIN; HUMAN constitution; RESEARCH methodology; MEDICAL cooperation; OBESITY; RESEARCH; SEROTONIN uptake inhibitors; SYMPATHETIC nervous system; EVALUATION research; RANDOMIZED controlled trials; BLIND experiment; CITALOPRAM; THERAPEUTICS
- Publication
Journal of Internal Medicine, 2001, Vol 250, Issue 3, p219
- ISSN
0954-6820
- Publication type
journal article
- DOI
10.1046/j.1365-2796.2001.00881.x